Proposed Fundraising

Definitions contained within Appendix II to this Announcement apply, unless the context requires otherwise

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces, further to the announcement of 11 June 2025, a proposed equity fundraising (the "Fundraising") to raise funds to support the commercial scale up of a suite of next generation blood-based tests for the kidney transplant market.

The Fundraising, consisting of a placing (the "Placing") of new ordinary shares of 0.1 pence ("Ordinary Shares") in the capital of the Company, a subscription for new Ordinary Shares and a separate retail offer of new Ordinary Shares (the "WRAP Retail Offer") via the Winterflood Retail Access Platform (the "WRAP"), will be conducted at a price of 0.5 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents a discount of 42.9 per cent. to Verici Dx's closing mid-price on 18 July 2025 (being the last practicable day prior to the publication of this Announcement).

The Placing is conducted via an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this Announcement. The Placing is being made available to certain institutional investors but is not available to the public.

The Placing will involve the issue of not less than 1,000,000,000 new Ordinary Shares (the "Placing Shares"), representing at least 412.3 per cent. of the existing issued ordinary share capital of the Company. In addition, a US investor intends conditionally to subscribe for 7,439,092 new Ordinary Shares ("Subscription Shares") at the Issue Price via a direct subscription ("Subscription") and, separately, the Company is proposing a WRAP Retail Offer to new and existing shareholders for up to 100,000,000 new Ordinary Shares at the Issue Price to raise up to an additional £0.5 million (before expenses).

Fundraising summary:

• Verici Dx is conducting a Placing to raise a minimum of £5 million (before expenses) through the proposed issue of a minimum of 1,000,000,000 Placing Shares at the Issue Price.
• A US investor intends conditionally to subscribe for 7,439,092 Subscription Shares at the Issue Price, representing approximately £37,195 (approximately $50,000) (before expenses) in aggregate.
• The net proceeds of the Placing and Subscription, which are expected to amount to at least £5 million (before expenses), will provide the Company with additional working capital to support the commercial scale up of a suite of next generation blood-based tests for the kidney transplant market.
• Singer Capital Markets Securities Limited ("Singer Capital Markets") and Oberon Capital, a trading name of Oberon Investments Limited ("Oberon Capital"), are acting as Joint Brokers and Joint Bookrunners in respect of the Placing (together, the "Bookrunners"). Oberon Capital have been appointed as the Company's Joint Broker, working alongside Singer Capital Markets, with immediate effect.
• The final number and allocation of the Placing Shares will be determined by the Bookrunners in consultation with the Company and the result of the Placing will be announced as soon as practical after the release of this Announcement.
• Verici Dx will be conducting a conditional WRAP Retail Offer separately from the Placing and the Subscription to raise up to an additional £0.5 million (before expenses). A separate announcement will be made by the Company regarding the WRAP Retail Offer and its terms in due course.

At a general meeting of the Company held on 27 May 2025, allotment and disapplication of pre-emption rights authorities were obtained which enable the Directors to issue and allot new Ordinary Shares for cash up to a maximum aggregate nominal amount of £2,000,000 (representing 2,000,000,000 new Ordinary Shares in the capital of the Company) (the "May 2025 Authorities"). These May 2025 Authorities will be sufficient for the proposed Fundraising and will be used for the purposes of issuing any new Ordinary Shares pursuant to the Fundraising. Consequently, the Company would not need to obtain further authorities to issue and allot new Ordinary Shares in the Fundraising on a non-pre-emptive basis.

WRAP Retail Offer

In addition to the Placing and the Subscription, there will be a conditional WRAP Retail Offer to be launched by the Company separately to raise up to £0.5 million (before expenses) at the Issue Price. This will provide UK retail investors with an opportunity to participate in the Fundraising.

The WRAP Retail Offer will be subject to a minimum subscription of £100 per investor and will be open to new investors and existing shareholders of the Company within the United Kingdom. Those investors who subscribe for new Ordinary Shares pursuant to the WRAP Retail Offer (the "WRAP Retail Offer Shares") will do so pursuant to the terms and conditions of the WRAP Retail Offer contained in a separate announcement (the "WRAP Retail Offer Announcement") to be released by the Company in due course, following the issue of an announcement confirming the result of the Placing and the Subscription.

For the avoidance of doubt, the WRAP Retail Offer Shares are not part of the Placing and the Subscription and do not form part of the Placing Shares and the Subscription Shares. The WRAP Retail Offer will be conditional on completion of the Placing and the Subscription. Details on admission of WRAP Retail Offer Shares to trading on AIM will be included in the WRAP Retail Offer announcement.

Admission to AIM

Application will be made to the London Stock Exchange for admission of the Placing Shares and the Subscription Shares (together the "New Ordinary Shares") to trading on AIM. It is expected that admission of all the New Ordinary Shares will become effective and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 24 July 2025 ("Admission").

Background, to and reasons for, the Fundraising

The Directors believe that Verici Dx has an exciting opportunity to accelerate commercial growth from a suite of next generation tests that address the kidney transplant market. The Directors believe the business has been significantly de-risked as it moves from product development into commercialisation. £31m has been raised to date to fund the development, clinical validation and commercial launch of the Company's testing suite. Two products are fully validated and commercially available, and the Company's lead product, Tutivia™, a test for acute rejection post-transplant, is now being used by 20 ordering centres in the US and is fully reimbursed by Medicare at a price of $2,650 a test, providing coverage for approximately 68% of US transplant patients.

The Directors believe that there is a large and growing market opportunity to address cases where current testing technology cannot provide accurate results and therefore are not utilized, as well as displacing existing tests within an already established biomarker test market.

The Directors are also pleased with the progress made so far with the Pre-Transplant Risk Assessment Test (PTRA) license with Thermo Fisher than was announced in Q4 2023. Sales volume based milestone payment and ongoing royalties are expected to be received as a result of the commercial progress.

The Company remains focused on rigorous cost control and current product development activities are necessarily managed within funds available from cash resources and future income.

As announced on 11 June 2025, as of 31 May 2025, the Company had unaudited net cash of $1.04 million providing a cash runway to at least the end of July 2025 (before the effects of any additional fundraising).

With minimum gross proceeds from the Placing and Subscription of £5 million, the Company's cash runway will be extended to mid Q2 2026.

Uses of Proceeds

The net proceeds of the Fundraising will be used, together with the Company's existing available resources, to:

• fund additional headcount to provide direct sales support for the scale up of Tutivia™ revenues. Verici Dx currently have only two sales representatives across 20 ordering centres. This accounts for c.10% of all kidney transplant procedures in the US. Additional resource will be used to support increased test usage within the existing ordering centres, as well as support expansion into other ordering centres;
• fund additional direct sales support to raise awareness of the Tutivia™. This will focus on increasing interactions with Key Opinion Leaders, attendance and presentations at key industry conferences and events, and the production of educational content for a targeted clinical audience;
• fund product development for the Company's urine platform and Protega™. This could help clinicians to determine the appropriate care pathways to delay of reduce progressive fibrosis;
• provide additional working capital.

Overall, the Directors consider that the investment of the net proceeds of the Fundraising has the potential to accelerate commercial growth and support the scale up of Tutivia™ revenues.

Current Trading

As announced on 30 June 2025, Q1 2025 saw a strong acceleration in Tutivia™ testing orders, with 292 tests recorded, a 68% increase compared to the previous quarter (Q4 2024), and nearly matching the total of 334 tests ordered during the entire FY 2024. Momentum has continued into Q2 2025, with 299 Tutivia™ tests ordered in the period.

The Company is also pleased to announce a successful appeal to MolDx, which has resulted in the effective date for Medicare billing of Tutivia™ tests being brought forward from 8 February 2025 to 21 November 2024. While forecasts remain unchanged at this stage, the earlier billing date enables the Company to invoice for a greater number of historical tests than previously anticipated, increasing confidence in meeting current market expectations for FY 2025.

Details of the Placing

The Placing Shares are being offered, subject to the satisfaction of certain conditions, including Admission occurring no later than 8.00 a.m. on 24 July 2025 (or such later time or date as the Joint Brokers may otherwise agree with the Company, being no later than 8.00 a.m. on 30 July 2025), set out in the Appendix I to this Announcement, by way of the Bookbuild which will be launched immediately following this Announcement.

Singer Capital Markets and Oberon Capital are acting as the Joint Brokers and Bookrunners in connection with the Placing. The number of Placing Shares will be agreed by the Company in conjunction with the Bookrunners following the close of the Bookbuild, and the result of the Placing will be announced as soon as practicable thereafter ("Results of Placing Announcement"). The timing of the closing of the Bookbuild, acceptance of any orders received after the Results of Placing Announcement, final allocations of the Placing Shares and the total size of the Placing shall be determined at the absolute discretion of the Company and the Bookrunners. The Placing is not being underwritten by Singer Capital Markets, Oberon Capital or any other person.

The Company has obtained clearance from HM Revenue & Customs ("HMRC") confirming that the Company is a qualifying company for the purposes of the Enterprise Investment Scheme ("EIS") (the "EIS Advance Assurance"). As part of the Placing, the Company is seeking to raise funds by the issue of Placing Shares to Venture Capital Trusts ("VCTs") and investors seeking tax relief under EIS (together the "EIS/VCT Placing Shares") (the "EIS/VCT Placing"). The raising of funds via the issue of the balance of the Placing Shares is referred to herein as the "Non-EIS/VCT Placing".

The EIS/VCT Placing Shares to be issued pursuant to the Placing are intended to rank as "eligible shares" for the purposes of EIS and VCT investors and a "qualifying holding" for the purposes of an investment by VCTs, each pursuant to the relevant respective sections of the Income Tax Act 2007 ("ITA 2007"). The Company has obtained the EIS Advance Assurance and the Company has also obtained a written opinion from specialist tax advisers confirming that the Company would, subject to the relevant limits on such issuances, be able to issue the EIS/VCT Placing Shares as "eligible shares" under the relevant sections of the ITA 2007. Neither the Company nor the Directors give any warranties or undertakings that EIS reliefs or VCT reliefs will be granted in respect of the EIS/VCT Placing Shares. Neither the Company nor the Directors give any warranties or undertakings that EIS reliefs or VCT reliefs, if granted, will not be withdrawn. If the Company carries on activities beyond those disclosed to HMRC then shareholders may cease to qualify for the tax benefits. Placees must take their own advice and rely on it.

Related Party Transactions

Christopher Mills / Harwood Capital LLP(1) ("Harwood Capital"), a Substantial Shareholder in the Company, has/have indicated their intention to participate in the Placing and such participation would constitute related party transactions under Rule 13 of the AIM Rules. Further details of any participation will be set out in the Result of Placing Announcement.

The Placing is also expected to include the participation of certain directors, and such participation would also constitute a related party transaction under Rule 13 of the AIM Rules. Further details of this participation will be set on in the Result of Placing Announcement.

Principal Risks and Material Uncertainties

The principal risks and uncertainties of the Group, which the Directors believe could materially affect the Group's ability to achieve its financial and operating objectives, are detailed on pages 16 to 19 of the 2024 Annual Report and Accounts (published on 7 July 2025 and available on the Company's website at https://vericidx.com/investors/annual-reports/). Those risks and uncertainties do not purport to be an exhaustive list and do not necessarily comprise all of the risks to which the Group is exposed. In particular, the Group's performance is likely to be affected by changes in market and/or economic conditions and in legal, accounting, regulatory and tax requirements. If any of the risks and uncertainties set out in the 2024 Annual Report and Accounts were to materialise, the Group's business, financial condition, results, prospects and/or future operations may be materially adversely affected. Additional risks and uncertainties not presently known to the Directors, may also have an adverse effect upon the Group's business, financial condition, results, prospects and/or future operations.

Expected Timetable of Principal Events

2025

​

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Information to Distributors

UK Product Governance Requirements

EU Product Governance Requirements

APPENDIX I

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING

Each Placee which confirms its agreement to the relevant Joint Broker (whether orally or in writing) to subscribe for Placing Shares under the Placing, hereby agrees with such Joint Broker and the Company that it will be bound by these terms and conditions and will be deemed to have accepted them.

The Joint Brokers may require any Placee to agree to such further terms and/or conditions and/or give such additional warranties and/or representations as it (in its absolute discretion) sees fit and/or may require any such Placee to execute a separate placing letter.

The Joint Brokers make no representation to any Placees regarding an investment in the Placing Shares. Neither of the Joint Brokers nor any of their respective affiliates, agents, directors, officers, employees or consultants makes any representation to any Placees regarding an investment in the Placing Shares. The Placing does not constitute a recommendation or financial product advice and the Joint Brokers have not had regard to particular objectives, financial situation and needs for each of the Placees.

• the Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in the United Kingdom other than Qualified Investors or in circumstances in which the prior consent of the Joint Brokers has been given to the offer or resale; or
• it is a Qualified Investor within the meaning of Article 2(e) of the EU Prospectus Regulation; and
• in the case of any Placing Shares acquired by it as a financial intermediary, as that term is used in Article 5(1) of the EU Prospectus Regulation:
• the Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in a Relevant State other than Qualified Investors or in circumstances in which the prior consent of the Joint Brokers has been given to the offer or resale; or

The Company and the Joint Brokers will each rely upon the truth and accuracy of the foregoing representations, warranties, acknowledgements and agreements. Each Placee hereby agrees with the Joint Brokers and the Company to be bound by these terms and conditions as being the terms and conditions upon which Placing Shares will be issued. A Placee shall, without limitation, become so bound if either Joint Broker confirms to such Placee its allocation of Placing Shares.

No prospectus

Each Placee, by participating in the Placing, agrees that the content of the Placing Documents is exclusively the responsibility of the Company and confirms that it has neither received nor relied on any information (other than the Publicly Available Information), representation, warranty or statement made by or on behalf of either of the Joint Brokers or the Company or any other person and none of the Joint Brokers, the Company nor any other person acting on such person's behalf nor any of their respective affiliates has or shall have any responsibility or liability for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement (regardless of whether or not such information, representation, warranty or statement was given or made by or on behalf of any such persons). Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing.

Details of the Placing Agreement and the Placing Shares

Singer Capital Markets and Oberon are acting as joint brokers and joint bookrunners in connection with the Placing and have entered into the Placing Agreement with the Company under which, on the terms and subject to the conditions set out in the Placing Agreement, Singer Capital Markets and Oberon, as agents for and on behalf of the Company, have agreed to use their reasonable endeavours to procure placees for the Placing Shares. The Placing is not being underwritten by Singer Capital Markets, Oberon or any other person.

The price per Ordinary Share at which the Placing Shares are to be placed is 0.5 pence (the "Issue Price"). The final number of Placing Shares will be determined by the Company, Singer Capital Markets and Oberon at the close of the Bookbuild and will be set out in the executed terms of placing (the "Terms of Placing"). The timing of the closing of the book and allocations are at the discretion of the Company, Singer Capital Markets and Oberon. Details of the number of Placing Shares will be announced as soon as practicable after the close of the Bookbuild.

The Placing Shares have been or will be duly authorised and will, when issued, be credited as fully paid up and will be issued subject to the Company's Articles of Association and rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of the Ordinary Shares after the date of issue of the Placing Shares, and will on issue be free of all pre-emption rights, claims, liens, charges, encumbrances and equities.

Application for listing and admission to trading

It is expected that Admission of the Placing Shares will become effective at 8.00 a.m. on 24 July 2025 (or such later time or date as the Joint Brokers may agree with the Company, being no later than 8.00 a.m. on 30 July 2025) and that dealings in the Placing Shares on AIM will commence at that time.

Bookbuild

Singer Capital Markets and Oberon will today commence the accelerated bookbuilding process to determine demand for participation in the Placing by Placees (the "Bookbuild"). This Appendix I gives details of the terms and conditions of, and the mechanics of participation in, the Placing. No commissions will be paid to Placees or by Placees in respect of any Placing Shares.

Oberon, Singer Capital Markets and the Company shall be entitled to effect the Placing by such alternative method to the Bookbuild as they may, in their sole discretion, determine.

Participation in, and principal terms of, the Placing

1. Singer Capital Markets and Oberon are acting as joint brokers and joint bookrunners to the Placing, as agents for and on behalf of the Company, on the terms and subject to the conditions of the Placing Agreement. SCM Advisory is acting as nominated adviser to the Company in connection with the Placing and Admission. Each of Oberon, Singer Capital Markets and SCM Advisory are authorised and regulated entities in the United Kingdom by the FCA and are acting exclusively for the Company and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than the Company in relation to the matters described in this Announcement. SCM Advisory's responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company, any director of the Company or to any other person.

• Participation in the Placing will only be available to persons who may lawfully be, and are, invited to participate by Oberon and Singer Capital Markets. Oberon and/or Singer Capital Markets may itself agree to be a Placee in respect of all or some of the Placing Shares or may nominate any member of its group to do so. Oberon, Singer Capital Markets and any of their respective affiliates are entitled to enter bids in the Bookbuild as principal.
• The Bookbuild, if successful, will establish the aggregate amount payable to Singer Capital Markets and Oberon, as settlement agents for the Company, by all Placees whose bids are successful. The final number of Placing Shares will be agreed between Singer Capital Markets, Oberon and the Company following completion of the Bookbuild. Following a successful completion of the Bookbuild, the Company will confirm the closing of the Placing via the Result of Placing Announcement.
• To bid in the Bookbuild, prospective Placees should communicate their bid orally by telephone or in writing to their usual sales contact at Singer Capital Markets or Oberon. Each bid should state the aggregate number of Placing Shares which the prospective Placee wishes to subscribe for at the Issue Price. Bids may be scaled down by Singer Capital Markets and Oberon on the basis referred to in paragraph 6 below. Singer Capital Markets and Oberon reserve the right not to accept bids or to accept bids in part rather than in whole. The acceptance of the bids shall be at the absolute discretion of the Joint Brokers, subject to agreement with the Company.
• The Bookbuild will open with immediate effect following release of this Announcement and is expected to close no later than 5.00 p.m. on 21 July 2025 but may be closed earlier or later at the discretion of the Joint Brokers. The Joint Brokers may, in agreement with the Company, accept bids that are received after the Bookbuild has closed. The Company reserves the right (upon the prior agreement of the Joint Brokers) to vary the number of Placing Shares to be issued pursuant to the Placing, in its absolute discretion.
• Allocations of the Placing Shares will be determined by the Joint Brokers after consultation with the Company (and in accordance with the allocation policies as have been supplied by the Joint Brokers to the Company in advance of such consultation). Allocations will be confirmed orally by the Joint Brokers and a trade confirmation will be despatched as soon as possible thereafter. The oral confirmation by either Joint Broker to such Placee constitutes an irrevocable legally binding commitment upon such person (who will at that point become a Placee), in favour of the relevant Joint Broker and the Company, to subscribe for the number of Placing Shares allocated to it and to pay the Issue Price in respect of each such share on the terms and conditions set out in this Appendix I and in accordance with the Company's Articles of Association. A bid in the Bookbuild will be made on the terms and subject to the conditions in this Appendix I and will be legally binding on the Placee on behalf of which it is made and except with the relevant Joint Broker's consent, such commitment will not be capable of variation, termination, rescission or revocation after the time at which it is submitted.
• Each Placee will have an immediate, separate, irrevocable and binding obligation, owed to each Joint Broker, as agent for the Company, to pay to it (or as it may direct) in cleared funds an amount equal to the product of the Issue Price and the number of Placing Shares such Placee has agreed to acquire and the Company has agreed to allot and issue to that Placee.
• To the fullest extent permissible by law, none of Singer Capital Markets, Oberon, the Company nor any of their respective affiliates, agents, directors, officers or employees shall have any responsibility or liability (whether in contract, tort or otherwise) to any Placee (or to any other person whether acting on behalf of a Placee or otherwise). In particular, none of Singer Capital Markets, Oberon, the Company, nor any of their respective affiliates, agents, directors, officers or employees shall have any responsibility or liability (including to the extent permissible by law, any fiduciary duties) in respect of the Joint Brokers' conduct of the Placing or of such alternative method of effecting the Placing as the Joint Brokers and the Company may agree.
• The Placing Shares will be issued subject to the terms and conditions of this Appendix I and each Placee's commitment to subscribe for Placing Shares on the terms set out herein will continue notwithstanding any amendment that may in future be made to the terms and conditions of the Placing and Placees will have no right to be consulted or require that their consent be obtained with respect to the Company's or the Joint Brokers' conduct of the Placing.

Conditions of the Placing

The Placing is conditional, amongst others, upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms. The Joint Brokers' obligations under the Placing Agreement are conditional on customary conditions, including (amongst others) (the "Conditions"):

• the performance by the Company of certain specified obligations under the Placing Agreement to the extent that they fall to be performed prior to Admission;
• agreement by the Company and the Joint Brokers of the final number of Placing Shares to be issued at the Issue Price pursuant to the Placing and the allocation of such Placing Shares to Placees;
• each of the warranties given by the Company contained in the Placing Agreement being true, accurate and not misleading: (i) as at and on the date of the Placing Agreement; (ii) as at the time of the execution of the Terms of Placing; and (iii) as at and on Admission, in each case, as though they had been given and made at such times and on such dates by reference to the facts and circumstances from time to time subsisting;
• no matter having arisen in respect of which indemnification or contribution may be sought from the Company by any Indemnified Person (such term as defined in the Placing Agreement) under the Placing Agreement;
• the Company having allotted, subject only to Admission, the New Ordinary Shares;
• delivery by the Company of certain customary documents to the Joint Brokers as requested under the terms of the Placing Agreement;
• SCM Advisory not having exercised their rights to terminate the Placing Agreement; and
• Admission occurring no later than 8.00 a.m. on 24 July 2025 (or such later time or date as the Joint Brokers may otherwise agree with the Company, being no later than 8.00 a.m. on 30 July 2025) (the "Closing Date").

The Joint Brokers may, at their discretion and upon such terms as it thinks fit, waive compliance by the Company with the whole or any part of any of its obligations in relation to the Conditions or extend the time or date provided for fulfilment of any such Conditions in respect of all or any part of the performance thereof, save in respect of Conditions 6 and 9 above. Any such extension or waiver will not affect Placees' commitments as set out in this Appendix I.

If: (i) any of the Conditions are not fulfilled or (where permitted) waived by the Joint Brokers by the relevant time or date specified (or such later time or date the Joint Brokers may agree with the Company, being no later than 8.00 a.m. on 30 July 2025); or (ii) the Placing Agreement is terminated in the circumstances specified below under "Right to terminate under the Placing Agreement", the Placing will not proceed and the Placees' rights and obligations hereunder in relation to the Placing Shares shall cease and terminate at such time and each Placee agrees that no claim can be made by it or on its behalf (or any person on whose behalf the Placee is acting) in respect thereof.

Neither of the Joint Brokers nor the Company, nor any of their respective affiliates, agents, directors, officers or employees shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision they may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any Condition to the Placing (or any part of it), nor for any decision they may make as to the satisfaction of any Condition or in respect of the Placing generally (or any part of it), and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of the relevant Joint Broker. Placees will have no rights against the relevant Joint Broker or any of their respective members, directors or employees under the Placing Agreement pursuant to the Contracts (Rights of Third Parties) Act 1999 (as amended) or otherwise.

Right to terminate under the Placing Agreement

SCM Advisory is entitled, at any time before Admission, to terminate the Placing Agreement in accordance with its terms in certain circumstances, including (amongst other things) in the event that:

• there has been a breach by the Company of any of its obligations, undertakings or covenants under the Placing Agreement which SCM Advisory considers is material;
• in the opinion of SCM Advisory (acting in good faith), there has been a Material Adverse Change;
• a matter having arisen which is likely to give rise to an indemnity claim under the Placing Agreement which the SCM Advisory considers is material;
• there has occurred, or in the opinion of SCM Advisory (acting in good faith) it is reasonably likely that there will occur, certain customary force majeure events;
• notice has been given by SCM Advisory to the Company to terminate its role as Nominated Adviser or any matter arises which SCM Advisory considers (acting in good faith) may adversely affect its ability to perform its functions under the AIM Rules or the AIM Rules for Nominated Advisers or fulfil the obligations of a nominated adviser to the Company; or
• if the Company's application for Admission is withdrawn or refused by the London Stock Exchange or, in the opinion of SCM Advisory (acting in good faith), will not be granted.

By participating in the Placing, each Placee agrees that (i) the exercise by the Joint Brokers or SCM Advisory (as the case may be) of any right of termination or of any other discretion under the Placing Agreement shall be within the absolute discretion of the relevant Joint Broker or SCM Advisory (as the case may be) and that it need not make any reference to, or consult with, Placees and that it shall have no liability to Placees whatsoever in connection with any such exercise or failure to so exercise and (ii) its rights and obligations terminate only in the circumstances described above under "Right to terminate under the Placing Agreement" and "Conditions of the Placing", and its participation will not be capable of rescission or termination by it after oral confirmation by the relevant Joint Broker of the allocation and commitments following the close of the Bookbuild.

Venture Capital Trust ("VCT") Schemes

The Company received an opinion from specialist tax advisers on 17 July 2025, stating that, based on information provided by the Company, and notwithstanding that many aspects of the VCT legislation are judgmental, that they expect that investments in Ordinary Shares in the Company by a VCT would be regarded as qualifying holdings for the purposes of Part 6 of the Income Tax Act 2007 and would be regarded as "eligible shares" as defined in section 285(3A) of that Act, provided that the investment by the VCT (including any existing investment in the Company) will not exceed 15% by value of its total investments at the date of the investment. If the Company carries on activities beyond those disclosed previously to HMRC, then shareholders may cease to qualify for these tax benefits. Investors must take their own advice and rely on it.

HMRC can no longer consider applications to receive advance assurance that a company is a qualifying company for the purposes of the Venture Capital Trust rules where the details of the potential qualifying holding are not given. The advice received by the Company does not guarantee the availability to any Placee of any form of relief under the relevant legislation for VCT schemes and there can be no certainty that VCT eligibility will apply.

The status of the EIS/VCT Placing Shares as a qualifying holding for VCT purposes will in any event be conditional (amongst other things) on the qualifying conditions being satisfied throughout the period of ownership by the Company. There can be no assurance that the Company will conduct its activities in a way that will secure or retain qualifying status for VCT purposes (and indeed circumstances may arise where the directors of the Company believe that the interests of the Group are not served by seeking to retain such status). Further, the conditions for VCT Relief are complex and relevant investors are recommended to seek their own professional advice before investing. This paragraph is without prejudice to any separate comfort letter which may have been given by the Company to certain VCT investors in connection with their investment.

Enterprise Investment Scheme ("EIS")

The Company has obtained clearance from HM Revenue & Customs ("HMRC") that it is a qualifying company for the purposes of the Enterprise Investment Scheme ("EIS Advance Assurance").

The EIS Advance Assurance does not guarantee to any particular Placee the availability of any form of relief under the relevant legislation for the EIS. The EIS/VCT Placing Shares qualifying for EIS Relief will in any event be conditional (amongst other things) on the qualifying conditions being satisfied throughout the period of ownership both by the Company and (as regards those conditions to be met by the investor) the investor throughout a period of at least three years from the date of issue. There can be no assurance that the Company will conduct its activities in a way that will secure or retain qualifying status for EIS purposes (and indeed circumstances may arise where the directors of the Company believe that the interests of the Group are not served by seeking to retain such status). Further, the conditions for EIS Relief are complex and relevant investors are recommended to seek their own professional advice before investing. This paragraph is without prejudice to any separate comfort letter which may have been given by the Company to certain EIS investors in connection with the EIS/VCT Placing.

Restriction on Further Issue of Shares

The Company has undertaken to the Joint Brokers that, between the date of the Placing Agreement and a period of 90 days from Admission (the "Restricted Period"), neither the Company nor any of its subsidiaries will, without the prior written consent of the Joint Brokers, directly or indirectly, offer, issue, lend, sell or contract to sell, issue options in respect of or otherwise dispose of or announce an offering or issue of any Ordinary Shares (or any interest therein or in respect thereof) or any other securities exchangeable for or convertible into, or substantially similar to, Ordinary Shares or enter into any transaction with the same economic effect as, or agree to do, any of the foregoing (whether or not legally or contractually obliged to do so) provided that the foregoing restrictions shall not restrict the ability of the Company or any other member of the Group during the Restricted Period to grant options under, or the allotment and issue of shares pursuant to options under, any employee or non-executive share or option schemes or long term incentive plans of the Company (in accordance with its normal practice) or enter into any commitment or agreement or arrangement or knowingly do or permit to be done any other act or thing which, in any such case, constitutes a significant new matter which would give rise to any obligation to make any announcement to the London Stock Exchange or which may (other than as referred to in the Placing Documents) involve any increase in or obligation (whether contingent or otherwise) to allot any of the capital of the Company.

By participating in the Placing, Placees agree that the exercise by the Joint Brokers of any power to grant consent to the undertaking by the Company of a transaction which would otherwise be subject to the restrictive provisions on further issuance under the Placing Agreement shall be within the absolute discretion of the Joint Brokers and that it need not make any reference to, or consult with, Placees and that it shall have no liability to Placees whatsoever in connection with any such exercise of the power to grant consent.

Registration and Settlement

Settlement of transactions in the Placing Shares (ISIN: GB00BM8HZD43) following Admission will take place within the system administered by Euroclear UK & International Limited ("CREST"), subject to certain exceptions. The Joint Brokers reserve the right to require settlement for, and delivery of, the Placing Shares (or any part thereof) to Placees by such other means that they may deem necessary if delivery or settlement is not possible or practicable within the CREST system or would not be consistent with the regulatory requirements in the Placee's jurisdiction.

Following the close of the Bookbuild, each Placee to be allocated Placing Shares in the Placing will be sent a trade confirmation stating the number of Placing Shares allocated to them at the Issue Price, the aggregate amount owed by such Placee to the relevant Joint Broker and settlement instructions. Each Placee agrees that it will do all things necessary to ensure that delivery and payment is completed in accordance with the standing CREST or certificated settlement instructions in respect of the Placing Shares that it has in place with the relevant Joint Broker.

The Company will deliver (or will procure the delivery of) the Placing Shares to a CREST account operated by each Joint Broker as agent for the Company and each Joint Broker will enter its delivery instruction into the CREST system. The input to CREST by a Placee of a matching or acceptance instruction will then allow delivery of the relevant Placing Shares to that Placee against payment.

It is expected that settlement in respect of the Placing Shares will take place in respect of the Placing Shares on 24 July 2025. It is expected that the EIS/VCT Placing Shares will be allotted unconditionally to potential Placees on 24 July 2025 (or such later date as the Company and the Joint Brokers may agree in writing, being no later than 30 July 2025). The allotment and issue of the EIS/VCT Placing Shares is not conditional upon the allotment and issue of the balance of the Placing Shares. However, it is conditional, inter alia, on:

• the performance by the Company of certain specified obligations under the Placing Agreement in so far as the same fall to be performed prior to completion of the EIS/VCT Placing;
• the Placing Agreement having been entered into and it having not been terminated prior to the issue of the EIS/VCT Placing Shares; and
• the satisfaction or, where appropriate, the waiver of all other conditions set out in the Placing Agreement relating to the issue of the EIS/VCT Placing Shares.

The Joint Brokers will use the Client Assets Sourcebook ("CASS") delivery versus payment exemption (under CASS 6.1.12R and 7.11.14R within the FCA Handbook Client Assets Sourcebook) with regard to settlement of shares and/or funds, in connection with the Placing.

Each Placee is deemed to agree that, if it does not comply with these obligations, the Joint Brokers may sell any or all of the Placing Shares allocated to that Placee on such Placee's behalf and retain from the proceeds, for the relevant Joint Broker's account and benefit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable for any shortfall below the aggregate amount owed by it and will be required to bear any stamp duty or stamp duty reserve tax or other taxes or duties (together with any interest or penalties) imposed in any jurisdiction which may arise upon the sale of such Placing Shares on such Placee's behalf.

If Placing Shares are to be delivered to a custodian or settlement agent, Placees should ensure that the trade confirmation is copied and delivered immediately to the relevant person within that organisation. Insofar as Placing Shares are issued in a Placee's name or that of its nominee or in the name of any person for whom a Placee is contracting as agent or that of a nominee for such person, such Placing Shares should, subject as provided below, be so registered free from any liability to UK stamp duty or stamp duty reserve tax. If there are any circumstances in which any stamp duty or stamp duty reserve tax or other similar taxes or duties (including any interest and penalties relating thereto) is payable in respect of the allocation, allotment, issue, sale, transfer or delivery of the Placing Shares (or, for the avoidance of doubt, if any stamp duty or stamp duty reserve tax is payable in connection with any subsequent transfer of or agreement to transfer Placing Shares), neither of the Joint Brokers nor the Company shall be responsible for payment thereof.

Representations, warranties, undertakings and acknowledgements

By participating in the Placing each Placee (and any person acting on such Placee's behalf) irrevocably acknowledges, confirms, undertakes, represents, warrants and agrees (as the case may be) with the Joint Brokers (in their joint capacities as broker, bookrunner and placing agent of the Company in respect of the Placing) and the Company, in each case as a fundamental term of their application for Placing Shares, the following (save where the Joint Brokers expressly agree in writing to the contrary):

1. it has read and understood this Announcement in its entirety and that its participation in the Bookbuild and the Placing and its acquisition of the Placing Shares is subject to and based upon all the terms, conditions, representations, warranties, indemnities, acknowledgements, agreements and undertakings and other information contained herein and that it has not relied on, and will not rely on, any information given or any representations, warranties or statements made at any time by any person in connection with Admission, the Placing, the Company, the Placing Shares or otherwise, other than the information contained in this Announcement and the Publicly Available Information;

3. (a) it has made its own assessment of the Company, the Placing Shares and the terms of the Placing based on this Announcement (including this Appendix I) and any Publicly Available Information; (b) the Ordinary Shares are admitted to trading on AIM and that the Company is therefore required to publish certain business and financial information in accordance with MAR and rules and regulations of the London Stock Exchange (including the AIM Rules) (collectively and together with the information referred to in (a) above, the "Exchange Information") which includes a description of the Company's business and the Company's most recent balance sheet and profit and loss account, and similar statements for preceding financial years, and that it has reviewed such Exchange Information and that it is able to obtain or access such information, or comparable information concerning any other publicly traded company, in each case without undue difficulty; and (c) it has had access to such financial and other information (including the business, financial condition, prospects, creditworthiness, status and affairs of the Company, the Placing and the Placing Shares) concerning the Company, the Placing and the Placing Shares as it has deemed necessary in connection with its own investment decision to subscribe for any of the Placing Shares and has satisfied itself that the information is still current and has relied on that investigation for the purposes of its decision to participate in the Placing;

• to be bound by the terms of the Articles of Association of the Company;
• the person whom it specifies for registration as holder of the Placing Shares will be (a) itself or (b) its nominee, as the case may be. Neither of the Joint Brokers nor the Company will be responsible for any liability to stamp duty or stamp duty reserve tax or other similar taxes or duties imposed in any jurisdiction (including interest and penalties relating thereto) ("Indemnified Taxes"). Each Placee and any person acting on behalf of such Placee agrees to indemnify each of the Joint Brokers and the Company on an after-tax basis in respect of any Indemnified Taxes;
• neither of the Joint Brokers nor any of their respective affiliates, agents, directors, officers and employees accepts any responsibility for any acts or omissions of the Company or any of the directors of the Company or any other person in connection with the Placing;
• time is of the essence as regards its obligations under this Appendix I;
• any document that is to be sent to it in connection with the Placing will be sent at its risk and may be sent to it at any address provided by it to the Joint Brokers;
• it has not received (and will not receive) a prospectus or other offering document in connection with the Bookbuild, the Placing or the Placing Shares and acknowledges that no prospectus or other offering document (a) is required under the UK Prospectus Regulation or other applicable law; and (b) has been or will be prepared in connection with the Placing and, in particular, that the WRAP Retail Offer referred to in this Announcement is separate from the Placing and does not form part of any offer or agreement concerning the Placing and/or any Placing Shares;
• in connection with the Placing, each of the Joint Brokers and any of their respective affiliates acting as an investor for its own account may subscribe for Placing Shares in the Company and in that capacity may retain, purchase or sell for its own account such Placing Shares in the Company and any securities of the Company or related investments and may offer or sell such securities or other investments otherwise than in connection with the Placing. Accordingly, references in this Announcement to the Placing Shares being issued, offered or placed should be read as including any issue, offering or placement of such shares in the Company to each of the Joint Brokers or any of their respective affiliates acting in such capacity;
• either of the Joint Brokers and their respective affiliates may enter into financing arrangements and swaps with investors in connection with which such Joint Broker and any of their respective affiliates may from time to time acquire, hold or dispose of such securities of the Company, including the Placing Shares;
• neither of the Joint Brokers intends to disclose the extent of any investment or transactions referred to in paragraphs 11 and 12 above otherwise than in accordance with any legal or regulatory obligation to do so;
• neither of the Joint Brokers owes any fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings or indemnities in the Placing Agreement;
• its participation in the Placing is on the basis that it is not and will not be a client of either of the Joint Brokers in connection with its participation in the Placing and that neither of the Joint Brokers has any duties or responsibilities to it for providing the protections afforded to its clients or customers or for providing advice in relation to the Placing nor in respect of any representations, warranties, undertakings or indemnities contained in the Placing Agreement nor for the exercise or performance of any of its rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;
• the content of the Placing Documents and the Publicly Available Information has been prepared by and is exclusively the responsibility of the Company (and such other persons specifically identified as accepting responsibility to certain parts thereto) and neither of the Joint Brokers nor any of their respective affiliates agents, directors, officers or employees nor any person acting on behalf of any of them is responsible for or has or shall have any responsibility or liability for any information, representation, warranty or statement contained in, or omission from, the Placing Documents, the Publicly Available Information or otherwise nor will they be liable for any Placee's decision to participate in the Placing based on any information, representation, warranty or statement contained in the Placing Documents, the Publicly Available Information or otherwise, provided that nothing in this paragraph excludes the liability of any person for fraudulent misrepresentation made by such person;
• it has neither received nor relied on any other information given, or representations, warranties or statements, express or implied, made, by either of the Joint Brokers nor the Company nor any of their respective affiliates, agents, directors, officers or employees acting on behalf of any of them (including in any management presentation delivered in respect of the Bookbuild) with respect to the Company, the Placing or the Placing Shares or the accuracy, completeness or adequacy of any information contained in the Placing Documents, or the Publicly Available Information or otherwise;
• neither of the Joint Brokers or the Company nor any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them has provided, nor will provide, it with any material or information regarding the Placing Shares or the Company or any other person other than the information in the Placing Documents or the Publicly Available Information; nor has it requested any of the Joint Brokers or the Company or any of their respective affiliates or any person acting on behalf of any of them to provide it with any such material or information;
• neither of the Joint Brokers nor the Company will be liable for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement, provided that nothing in this paragraph excludes the liability of any person for fraudulent misrepresentation made by that person;
• it may not rely, and has not relied, on any investigation that either of the Joint Brokers, any of their respective affiliates or any person acting on its behalf, may have conducted with respect to the Placing Shares, the terms of the Placing or the Company, and none of such persons has made any representation, express or implied, with respect to the Company, the Placing, the Placing Shares or the accuracy, completeness or adequacy of the information in the Placing Documents, the Publicly Available Information or any other information;
• in making any decision to subscribe for Placing Shares it:
• will not look to either of the Joint Brokers for all or part of any such loss it may suffer;
• is able to sustain a complete loss of an investment in the Placing Shares;
• has no need for liquidity with respect to its investment in the Placing Shares;
• will remain liable to the Company and/or either of the Joint Brokers for the performance of all its obligations as a Placee in respect of the Placing (regardless of the fact that it is acting for another person), and
• it and any person acting on its behalf is entitled to subscribe for the Placing Shares under the laws and regulations of all relevant jurisdictions that apply to it and that it has fully observed such laws and regulations, has capacity and authority and is entitled to enter into and perform its obligations as a subscriber of Placing Shares and will honour such obligations, and has obtained all such governmental and other guarantees, permits, authorisations, approvals and consents which may be required thereunder and complied with all necessary formalities to enable it to commit to this participation in the Placing and to perform its obligations in relation thereto (including, without limitation, in the case of any person on whose behalf it is acting, all necessary consents and authorities to agree to the terms set out or referred to in this Appendix I) and will honour such obligations and that it has not taken any action or omitted to take any action which will or may result in either of the Joint Brokers or the Company or any of their respective directors, officers, agents, employees or advisers acting in breach of the legal or regulatory requirements of any jurisdiction in connection with the Placing;
• it irrevocably appoints any duly authorised officer of each of the Joint Brokers as its agent for the purpose of executing and delivering to the Company and/or its registrars any documents on its behalf necessary to enable it to be registered as the holder of any of the Placing Shares for which it agrees to subscribe or purchase for upon the terms of this Appendix I;
• no action has been or will be taken by any of the Company or either of the Joint Brokers or any person acting on behalf of the Company or either of the Joint Brokers that would, or is intended to, permit a public offer of the Placing Shares in the United States or in any country or jurisdiction where any such action for that purpose is required;
• unless otherwise specifically agreed with the Joint Brokers, it is not and at the time the Placing Shares are subscribed for, neither it nor the beneficial owner of the Placing Shares will be, a resident of, nor have an address in, Australia, New Zealand, Japan, the Republic of South Africa or any province or territory of Canada;
• it may be asked to disclose in writing or orally to either of the Joint Brokers:
• if he or she is an individual, his or her nationality; or
• it understands that the Company has not undertaken to determine whether it will be treated as a passive foreign investment company ("PFIC") for US federal income tax purposes for the current year, or whether it is likely to be so treated for future years and neither the Company nor either of the Joint Brokers make any representation or warranty with respect to the same. Accordingly, neither the Company nor either of the Joint Brokers can provide any advice to United States investors as to whether the Company is or is not a PFIC for the current tax year, or whether it will be in future tax years. Accordingly, neither the Company nor either of the Joint Brokers undertakes to provide to United States investors or shareholders any information necessary or desirable to facilitate their filing of annual information returns, and United States investors and shareholders should not assume that this information will be made available to them;
• if it is a financial intermediary, as that term is used in Article 5(1) of the UK Prospectus Regulation, the Placing Shares acquired by it in the Placing will not be acquired on a non-discretionary basis on behalf of, nor will they be acquired with a view to their offer or resale to, persons in the United Kingdom other than Qualified Investors, or in circumstances in which the express prior written consent of either of the Joint Brokers has been given to each proposed offer or resale;
• if in the United Kingdom, unless otherwise agreed by the Joint Brokers, it is a "professional client" or an "eligible counterparty" within the meaning of Chapter 3 of COBS and it is purchasing Placing Shares for investment only and not with a view to resale or distribution;
• it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) relating to the Placing Shares in circumstances in which section 21(1) of FSMA does not require approval of the communication by an authorised person and it acknowledges and agrees that the Placing Documents have not and will not have been approved by either of the Joint Brokers in its capacity as an authorised person under section 21 of the FSMA and it may not therefore be subject to the controls which would apply if it was made or approved as a financial promotion by an authorised person;
• in order to ensure compliance with the Regulations, each of the Joint Brokers (for itself and as agent on behalf of the Company) or the Company's registrars may, in their absolute discretion, require verification of its identity. Pending the provision to the Joint Brokers or the Company's registrars, as applicable, of evidence of identity, definitive certificates in respect of the Placing Shares may be retained at the Joint Brokers' absolute discretion or, where appropriate, delivery of the Placing Shares to it in uncertificated form may be delayed at the Joint Brokers or the Company's registrars', as the case may be, absolute discretion. If within a reasonable time after a request for verification of identify the Joint Brokers (for itself and as agent on behalf of the Company) or the Company's registrars have not received evidence satisfactory to them, either of the Joint Brokers and/or the Company may, at its absolute discretion, terminate its commitment in respect of the Placing, in which event the monies payable on acceptance of allotment will, if already paid, be returned without interest to the account of the drawee's bank from which they were originally debited. Each Placee agrees to hold harmless and indemnify on an after-tax basis the Joint Brokers and the Company against any liability, loss or cost ensuing due to the failure to process such application, if such evidence or information as has been requested has not been provided by it in a timely manner;
• it (and any person acting on its behalf) has the funds available to pay for the Placing Shares for which it has agreed to subscribe and acknowledges and agrees that it will make payment in respect of the Placing Shares allocated to it in accordance with this Appendix I on the due time and date set out herein, failing which the relevant Placing Shares may be placed with other subscribers or sold as either of the Joint Brokers may in their discretion determine and without liability to such Placee, who will remain liable for any amount by which the net proceeds of such sale falls short of the product of the relevant Issue Price and the number of Placing Shares allocated to it and will be required to bear any stamp duty, stamp duty reserve tax or other taxes or duties (together with any interest, fines or penalties) imposed in any jurisdiction which may arise upon the sale of such Placee's Placing Shares;
• any money held in an account with Singer Capital Markets or Oberon on behalf of the Placee and/or any person acting on behalf of the Placee and/or any person acting on behalf of the Placee will not be treated as client money within the meaning of the relevant rules and regulations of the FCA made under the FSMA. Each Placee acknowledges that the money will not be subject to the protections conferred by the client money rules: as a consequence this money will not be segregated from the relevant Joint Broker's money in accordance with the client money rules and will be held by it under a banking relationship and not as trustee;
• its allocation (if any) of Placing Shares will represent a maximum number of Placing Shares which it will be entitled, and required, to subscribe for, and that the Joint Brokers or the Company may call upon it to subscribe for a lower number of Placing Shares (if any), but in no event in aggregate more than the aforementioned maximum;
• neither of the Joint Brokers nor any of their respective affiliates, nor any person acting on behalf of them, is making any recommendations to it, advising it regarding the suitability of any transactions it may enter into in connection with the Placing and neither Joint Broker is acting for it or its clients, and that neither Joint Broker will not be responsible for providing the protections afforded to its customers or for providing advice in respect of the transactions described in this Announcement;
• it acknowledges that its commitment to acquire Placing Shares on the terms set out in this Announcement and in the trade confirmation, contract note or other (oral or written) confirmation will continue notwithstanding any amendment that may in future be made to the terms and conditions of the Placing and that Placees will have no right to be consulted or require that their consent be obtained with respect to the Company's or either of the Joint Brokers' conduct of the Placing;
• the rights and remedies of the Company and the Joint Brokers under the terms and conditions in this Appendix I are in addition to any rights and remedies which would otherwise be available to each of them and the exercise or partial exercise of one will not prevent the exercise of others;
• these terms and conditions of the Placing and any agreements entered into by it pursuant to these terms and conditions and all agreements to acquire shares pursuant to the Placing, and all non-contractual or other obligations arising out of or in connection with them, shall be governed by and construed in accordance with the laws of England and it submits (on behalf of itself and on behalf of any person on whose behalf it is acting) to the exclusive jurisdiction of the English courts as regards any claim, dispute or matter arising out of any such contract (including any dispute regarding the existence, validity or termination of such contract or relating to any non- contractual or other obligation arising out of or in connection with such contract), except that enforcement proceedings in respect of the obligation to make payment for the Placing Shares (together with any interest chargeable thereon) may be taken by either the Company or either of the Joint Brokers in any jurisdiction in which the relevant Placee is incorporated or in which any of its securities have a quotation on a recognised stock exchange;
• it undertakes to each of the Joint Brokers at the time of making its commitment to subscribe for Placing Shares that it will confirm in writing to the relevant Joint Broker in the form of confirmation sent by the relevant Joint Broker to Placees the number of Placing Shares and it intends to subscribe for and in respect of which VCT Relief or EIS Relief will be sought (or which will otherwise comprise Relevant Funding) and those Placing Shares in respect of which such relief will not be sought (or which will otherwise not comprise Relevant Funding);
• it confirms that any of its clients, whether or not identified to either of the Joint Brokers or any of their respective affiliates, will remain its sole responsibility and will not become clients of the relevant Joint Broker or any of their respective affiliates for the purposes of the rules of the FCA or for the purposes of any other statutory or regulatory provision;
• that, if they are an existing shareholder of Ordinary Shares in the Company, they will not be eligible for EIS Relief in respect of any Placing Shares applied for by them;
• it agrees that the exercise of any right of termination by SCM Advisory or any right of waiver exercisable by the Joint Brokers contained in the Placing Agreement or the exercise of any discretion thereunder is within the absolute discretion of the Joint Brokers and SCM Advisory and the Joint Brokers and SCM Advisory will not have any liability to it whatsoever in connection with any decision to exercise or not exercise any such rights. Each Placee acknowledges that if (i) any of the conditions in the Placing Agreement are not satisfied (or, where relevant, waived); or (ii) the Placing Agreement is terminated; or (iii) the Placing Agreement does not otherwise become unconditional in all respects, the Placing will lapse and its rights and obligations hereunder shall cease and determine at such time and no claim shall be made by it in respect thereof; and
• a communication that the Placing or the book is "covered" (i.e. indicated demand from investors in the book equals or exceeds the amount of the securities being offered) is not any indication or assurance that the book will remain covered or that the Placing and securities will be fully distributed by the Joint Brokers. The Joint Brokers each reserve the right to take up a portion of the securities in the Placing as a principal position at any stage at its sole discretion, among other things, to take account of the Company's objectives, UK MiFID II requirements and/or its allocation policies.

The foregoing representations, warranties, confirmations, acknowledgements, agreements and undertakings are given for the benefit of the Company as well the Joint Brokers and are irrevocable. The Joint Brokers and the Company and their respective affiliates and others will rely upon the truth and accuracy of the foregoing representations, warranties, confirmations, acknowledgements, agreements and undertakings.

Each prospective Placee, and any person acting on behalf of such Placee, irrevocably authorises the Company and the Joint Brokers to produce this Announcement, pursuant to, in connection with, or as may be required by any applicable law or regulation, administrative or legal proceeding or official inquiry with respect to the matters set forth herein.

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) agrees to indemnify on an after-tax basis and hold the Company, the Joint Brokers and their respective affiliates, agents, directors, officers and employees harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings given by the Placee (and any person acting on such Placee's behalf) in this Appendix I or incurred by the Joint Brokers, the Company or any of their respective affiliates, agents, directors, officers or employees arising from the performance of the Placees' obligations as set out in this Announcement, and further agrees that the provisions of this Appendix I shall survive after completion of the Placing.

Singer Capital Markets Securities Limited and Oberon Capital, a trading name of Oberon Investments Limited, are each authorised and regulated by the FCA in the United Kingdom and are acting as joint brokers and joint bookrunners exclusively for the Company and no one else in connection with the Placing and will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

Taxation

Such agreement also assumes that the Placing Shares are not being acquired in connection with arrangements to issue depositary receipts or to issue or transfer the Placing Shares into a clearance service. If there are any such arrangements, or the settlement relates to any other dealings in the Placing Shares, stamp duty or stamp duty reserve tax or other similar taxes or duties may be payable, for which neither the Company nor the Joint Brokers will be responsible and the Placees shall indemnify the Company and each of the Joint Brokers on an after-tax basis for any stamp duty or stamp duty reserve tax or other similar taxes or duties (together with interest, fines and penalties) in any jurisdiction paid by the Company or either of the Joint Brokers in respect of any such arrangements or dealings. If this is the case, each Placee should seek its own advice and notify the relevant Joint Broker accordingly. Placees are advised to consult with their own advisers regarding the tax aspects of the subscription for Placing Shares.

The Company and the Joint Brokers are not liable to bear any taxes that arise on a sale of Placing Shares subsequent to their acquisition by Placees, including any taxes arising otherwise than under the laws of any country in the EEA. Each prospective Placee should, therefore, take its own advice as to whether any such tax liability arises and notify the relevant Joint Broker and the Company accordingly. Furthermore, each prospective Placee agrees to indemnify on an after-tax basis and hold each of the Joint Brokers and/or the Company and their respective affiliates harmless from any and all interest, fines or penalties in relation to stamp duty, stamp duty reserve tax and all other similar duties or taxes in any jurisdiction to the extent that such interest, fines or penalties arise from the unreasonable default or delay of that Placee or its agent.

All times and dates in this Announcement (including this Appendix I to the Announcement) may be subject to amendment. The Joint Brokers shall notify the Placees and any person acting on behalf of the Placees of any changes.

APPENDIX II

The following definitions apply throughout this Announcement unless the context otherwise requires: